Henry Bone, MD
Endocrinology, Diabetes & Metabolism · Detroit, MINPI 1598760688
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,325 of the $119,993 with a category attached, or 80.3%. Amgen accounts for 86.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $83,681 and has fallen 99.9% since, to $92 in 2025. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $944.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$104K
- Ipsen Bioscience Inc.$10K
- Radius Health, Inc.$5K
- Shire North American Group Inc$2K
- Ascendis Pharma Endocrinology Inc$147
Across 8 payments — averaging $2499.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$14K
- Shire North American Group Inc$5K
- Radius Health, Inc.$1K
What the payments were for
- Consulting fees$9,5488%
- Speaking & faculty fees$96,32580%
- Travel & lodging$10,5329%
- Food & beverage$3,5883%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 115 | $103,793 |
| Ipsen Bioscience Inc. | 1 | $9,548 |
| Radius Health, Inc. | 6 | $4,501 |
| Shire North American Group Inc | 4 | $2,005 |
| Ascendis Pharma Endocrinology Inc | 1 | $147 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$62,359
- EVENITY$31,644
- Tymlos$4,283
- NATPARA (PARATHYROID HORMONE)$2,005
How this compares
$119,993 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cinacalcet Hcl | 26 | $6,900 |
| Raloxifene Hcl | 66 | $3,263 |
| Amiloride-HydrochlorothiazideAmiloride/Hydrochlorothiazide | 60 | $2,407 |
| Indapamide | 117 | $1,624 |
| Calcitriol | 51 | $1,202 |
| Alendronate Sodium | 86 | $1,139 |
| Potassium Chloride | 25 | $820 |
| Levothyroxine Sodium | 12 | $88 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Detroit
- Shobana AthimulamDetroit$14K
- Wael TahaDetroit$12K
- Berhane SeyoumDetroit$11K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.